Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin for Uncomplicated Staphylococcus Aureus Bacteremia
NCT00062647Phase 2Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Aug 2003
- Primary completion
- Aug 2006
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of telavancin in Staphylococcus aureus bacteremia (SAB), sponsored by Cumberland Pharmaceuticals. Started Aug 2003; status: completed.
02
Drugs
telavancin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT00062647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062647.